Shares of XOMA Corp. (XOMA) plunged more than 77% on Wednesday following the failure of a phase III study of Gevokizumab in patients with Beh‡et’s disease uveitis, run by its partner Servier, to meet the primary endpoint.
Forex – financial instrument.Forex news
Shares of XOMA Corp. (XOMA) plunged more than 77% on Wednesday following the failure of a phase III study of Gevokizumab in patients with Beh‡et’s disease uveitis, run by its partner Servier, to meet the primary endpoint.